Metastatic Type II Papillary Renal Cell Carcinoma With Recurrent Complete Responses to Sunitinib: A Case Report With a Literature Review
CUREUS JOURNAL OF MEDICAL SCIENCE(2022)
Abstract
Papillary renal cell carcinoma (PRCC) is a less common subtype of kidney cancer and is typically more resistant to systemic treatments. This report describes a patient with metastatic type II PRCC who experienced two complete responses (CR) to the tyrosine kinase inhibitor (TKI) sunitinib. The patient remains on sunitinib with durable control of the disease. To the best of our knowledge, this is the first case of metastatic type II PRCC with CR to sunitinib.
MoreTranslated text
Key words
complete response, sunitinib, tyrosine kinase inhibitors, papillary, renal cell carcinoma
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined